Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine

Table 3

Proportion of patients free from nausea from day 1 to day 6.

Nausea-free	Ondansetron; Arm 1; Number (%)	Ondansetron + aprepitant; Arm 2; Number (%)
Day 1	35 (78)	32 (74)	0.45
Day 2	35 (78)	32 (74)	0.45
Day 3	34 (77)	30 (71)	0.35
Day 4	32 (73)	30 (71)	0.54
Day 5	30 (68)	32 (74)	0.27
Day 6	29 (67)	31 (74)	0.18